CD39 is expressed by a wide range of cutaneous T-cell lymphomas.

Date publication

avril 2024

Journal

Skin health and disease

Auteurs

Membres identifiés du Cancéropôle Est :
Pr BENSUSSAN Armand

Tous les auteurs :
Battesti G, Thonnart N, Bozonnat A, Ram-Wolff C, de Masson A, Bensussan A, Bagot M, Marie-Cardine A, Battistella M

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/38577051

Résumé

CD39, an ectoenzyme in the immunosuppressive CD39/CD73/adenosine pathway, known to promote solid tumour outgrowth and spreading, was investigated in both skin and blood compartments of cutaneous T cell lymphomas. CD39 was overexpressed by peripheral blood T-cells in Sezary syndrome and mycosis fungoides, and in skin-infiltrating lymphocytes of Sezary syndrome, mycosis fungoides, subcutaneous panniculitis-like T-cell lymphoma and primary cutaneous CD30-positive lymphoproliferation. Our study emphasizes the interest in using CD39/CD73/adenosine pathway blocking agents for cutaneous T cell lymphomas treatment.

Référence

Skin Health Dis. 2024 04;4(2):e334